Table 3

Sample and breast cancer characteristics

Study,
first author,
year,
country
Actual years of trialAge of
participants (years),
mean
(SD)
Intervention
(s)/control
Sample size (N)
Intervention(s)/
control
Race/ethnicity %Body mass index
(kg/m2), mean (SD) Intervention(s)/
control
Marital status (married %)Employment
status* (%)
Income status (high %)Education
(>high
school %)
Cancer
stage
Time of measurement (since diagnosis or treatment) at baseline or timingMenopausal status
(postmenopausal %)
Randomised control trials during treatment
Schmidt (2015)41 Germany2010–201352.2 (9.9)/
53.3 (10.2)
52/49NR25.7 (4.6)/
26.3 (4.9)
NRNRNRNR0–IIIDuring adjuvant chemotherapyNR
Courneya (2014)39 Canada2008–201150.1 (8.8)/50.5 (9.4)/
49.2 (8.4)
101/104/96White 84.725.2 (4.5)/
28.2 (6.5)/
26.0 (4.9)
64.541.954.364.80–IIICInitiating adjuvant chemotherapyNR
Steindorf (2014),30 Germany2011–201355.2 (9.5)/
56.4 (8.7)
80/80NR26.9 (5.4)/
27.6 (4.8)
NRNRNRNR0–IIIDuring radiotherapyNR
Chandwani (2014)36
USA
2006–200952.38 (1.35)/
51.14 (1.32)/
52.11 (1.34)
53/56/54White 64.7NR67.55755.774.30–IIIUndergoing radiotherapyNR
Travier (2015),37 Netherlands2010–201349.7 (8.2)/
49.5 (7.9)
102/102NR25.8 (4.4)/
26.6 (5.2)
76NRNR40.70–IIIWithin 6 weeks of diagnosis during chemotherapy38.2
Gokal (2016)40 UK2012–201352.08 (11.7)/
52.36 (8.9)
25/25NR27.20 (4.82)/
28.25 (5.83)
7686NR220–IIIDuring chemotherapy62
Randomised control trials after treatment
Cantarero-Villanueva (2012)38 Spain2009–201049(9)/48(9)38/40NRNR6158.2NR43.20–IIIAFinished coadjuvant treatment except hormone therapy65.6
Naumann34 (2012) USANR49.0 (10.0)/
49.0 (8.2)/
51.8 (11.5)
11/12/10NR27.3 (1.50)/
27.5 (1.49)/
27.4(1.49)c
NRNRNRNR0–IIIWithin 12 months of treatment completion except hormone therapyNR
Bower29 (2012) USA2007–201054.4 (5.7)/53.3 (4.9)16/15White 8724 (2.5)/25.3 (3.4)74NR83.8580–IIAt least 6 months post-treatment100
Cantarero-Villanueva33 (2013)
Spain
2009–201049 (7)/47(8)34/34NRNR6357.4NR44.20–IIIAFinished oncology treatment except hormone therapy in the previous 18 months72.1
Spahn35 (2013) GermanyNR58.1 (8.5)/
55.3 (11.4)
32/32NR26.6 (4.1)/
26.9 (4.3)
NRNRNRNRI–IIICompleted treatment except hormone therapy at least 3 months beforeNR (menopausal transition)
Ergun42 (2013)
Turkey
NR49.65 (8.25)/
55.05 (6.85)/
50.30 (10.37
20/20/20NR26.55 (4.40)/
28.64 (5.15)/
50.30 (10.37)
7747NR380–IIICompleted treatment100
Saxton32 (2014), UKNR55.8 (10)/
55.3 (8.8)
44/41White 9929.7 (3.5)/
31.1 (5.7)
68.2NRNRNR0–IIICompleted treatment 3–18 months previouslyNR
Rock6 (2015), USA2010–201256.4 (9.53)/
56.0 (9.47)
344/348White 79>25 for both groups66.991.6NR85.7I–IIICompleted treatment87.4
  • *Employed and retired and on sick leave.

  • Indicates original articles describing details about participant characteristics and/or intervention design.

  • ‡Adjusted mean (SE).